CME: Pathogen-Directed Respiratory Infection Care

CME: Pathogen-Directed Respiratory Infection Care
Author Information (click to view)

Helen W. Boucher, MD, FACP, FIDSA

Director, Infectious Diseases Fellowship Program
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Associate Professor of Medicine
Tufts University School of Medicine

Helen W. Boucher, MD, FACP, FIDSA, has indicated to Physician’s Weekly that she has worked as a consultant for Merck and Achtellion and as an editor for Elsev

Figure 1 (click to view)
Target Audience (click to view)

This activity is designed to meet the needs of physicians.

Learning Objectives(click to view)

Upon completion of the educational activity, participants should be able to:


  • Summarize the current state of antimicrobial-resistant bacterial respiratory tract pathogens.

Method of Participation(click to view)

Statements of credit will be awarded based on the participant reviewing monograph, correctly answer 2 out of 3 questions on the post test, completing and submitting an activity evaluation.  A statement of credit will be available upon completion of an online evaluation/claimed credit form at  You must participate in the entire activity to receive credit.  If you have questions about this CME/CE activity, please contact AKH Inc. at

Credit Available(click to view)


CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Physician’s Weekly’s.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.


AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support(click to view)

There is no commercial support for this activity.

Disclosures(click to view)

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use & Investigational Product(click to view)

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer(click to view)

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Faculty & Credentials(click to view)


Christopher Cole – Senior Editor
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Helen W. Boucher, MD, FACP, FIDSA
Discloses the following financial relationships with pharmaceutical or medical product manufacturers:
Actelion Pharmaceuticals, Inc; Merck & Co. Inc.

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditation
Discloses no financial relationships with pharmaceutical or medical product manufacturers.

AKH planners and reviewers have no relevant financial relationships to disclose.


Helen W. Boucher, MD, FACP, FIDSA (click to view)

Helen W. Boucher, MD, FACP, FIDSA

Director, Infectious Diseases Fellowship Program
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Associate Professor of Medicine
Tufts University School of Medicine

Helen W. Boucher, MD, FACP, FIDSA, has indicated to Physician’s Weekly that she has worked as a consultant for Merck and Achtellion and as an editor for Elsev

Greater efforts are needed to manage respiratory infections due to antibacterial-resistant bacteria. Improving the use of antibiotics with the most appropriate drug and optimal dose is critical to combatting the issue
Share on FacebookTweet about this on TwitterShare on LinkedIn

Antimicrobial resistance poses a serious public health threat and is an especially challenging issue when treating respiratory infections. Research shows that the number of pneumonia cases caused by antibiotic-resistant bacteria has risen substantially in recent years. These cases have been linked to higher mortality and morbidity, longer stays in intensive care, and increased costs due to inadequate therapy when compared with pneumonia caused by non-resistant pathogens.

“We’re in the middle of an antimicrobial resistance crisis in the United States,” says Helen W. Boucher, MD, FACP, FIDSA. “One of the biggest contributors to this issue is the overuse of antibiotics. Some clinicians are treating infections too broadly and prescribing unwarranted antibiotics. Although many respiratory infections are caused by viruses, antibiotics are often prescribed inappropriately to treat these infections.”


The Challenge

As with any infection, respiratory infections should be treated as narrowly as possible, according to Dr. Boucher, who co-authored a review article summarizing the current state of antimicrobial-resistant bacterial respiratory tract pathogens (Table) that was published in Current Opinion in Pulmonary Medicine. “The goal is to treat the exact pathogen that’s causing the infection, and nothing more. Treating beyond a specific pathogen can lead to overuse of antibiotics, resistance, and adverse effects for patients,” she says.

Dr. Boucher says strong, accurate diagnostic testing is required in order to appropriately prescribe antibiotics. “For pneumonia,” she says, “there are several new tools that are highly accurate in diagnosing the pathogen causing the infection. This allows for appropriate, pathogen-directed therapy. Pathogen-directed therapy also includes recognizing if the bacterium is susceptible or resistant to certain antibiotics.” Even when these factors are known, targeting antimicrobial-resistant bacteria can still be challenging because there are few therapeutic options available for treating respiratory infections.


Targeted Therapy

For healthcare- and ventilator-associated pneumonia, pseudomonas and MRSA are often the cause. “Interventions have been put in place to prevent pneumonia in most hospitals in the U.S.,” says Dr. Boucher, “but when it does occur, it is important to treat it quickly with powerful antibiotics that are meant to treat resistant organisms. In most cases, the cause is not immediately known, so most hospitals follow protocols that start therapy based on the statistically most common causes—typically MRSA and pseudomonas—and then perform diagnostic tests to narrow treatment to one or two drugs that treat the specific pathogen. If a certain pathogen like pseudomonas is known to be the cause, treatment should include agents that target that pathogen, not those that treat many other bacteria at the same time. Doing so provides the best treatment for a given infection and causes less damage to the rest of the patient’s body. It also helps in our global fight against antibiotic resistance.”

Before initiating empirical antibiotics for a respiratory infection caused by an unknown pathogen, clinicians should take into consideration a patient’s risk of having resistant pathogens and their institution’s susceptibility to such pathogens, according to Dr. Boucher. “This data should be used to determine the most appropriate antibiotics to use first, while awaiting diagnostic testing results,” she says. “Patients should then be followed daily to determine if diagnostic testing has provided any answers that allow for de-escalation of therapy.”


The Ultimate Goal

The successful use of targeted therapy relies on the accurate, rapid identification of pathogens and the recognition of susceptibility patterns, says Dr. Boucher. “While there has been progress in recent years, the current gold-standard technique of Gram stain and cultures or respiratory specimens takes 48 to 72 hours to process,” she says. Diagnostic techniques using molecular assays or mass spectrometry may provide accurate identification of pathogens within a few hours, but most research in this area has focused on detecting viral respiratory infections. Studies are needed to determine the validity of such diagnostics in detecting bacterial respiratory infections.

In the meantime, Dr. Boucher says clinicians should ask themselves the following questions when treating patients with a respiratory infection:

  • Do I know what the pathogen is?
  • Can I reduce antibiotic exposure?
  • Have I performed the right diagnostic tests?
  • Is there information that will allow me to stop using any of these antibiotics?
  • Are any of these antibiotics hurting the patient?

“Routinely asking these questions will help clinicians work toward the ultimate goal, which is treating patients with the most appropriate drugs for their infection,” Dr. Boucher says.

Readings & Resources (click to view)

Lee B, Boucher H. Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to ‘get smart’. Curr Opin Pulm Med. 2015;21:293-303. Available at

Zumla A, Memish Z, Maeurer M, et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis. 2014;14:1136-1149.

Kuti E, Patel A, Coleman C. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23:91-100.

Saravu K, Preethi V, Kumar R, et al. Determinants of ventilator associated pneumonia and its impact on prognosis. J Crit Care. 2012;27:322.e7-e14.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × five =